Phase III clinical trials of Campyvax are about to begin, backed by the US Department of Defense, developers Antex Biologics, of Gaithersburg, Maryland, USA, have reported.
The oral vaccine has been developed to provide protection against the gastroenteritis and diarrhea caused by Campylobacter jejuni.
Oral vaccine to protect against Campylobacter jejuni
The Phase II trial compared the effects of a 4-dose regimen with those of a 2-dose treatment - the subject of an earlier trial.
A range of tests showed the 4-dose treatment achieving significant improvements in immune response. On average, levels of interferon gamma increased by 12 times. A response was seen in about 85 per cent of volunteers.
Researcher Dr David Tribble, of the enteric diseases department of the US Naval Medical Research Center, said, "The enhanced immune response observed following the 4-dose regimen of Campyvax is particularly promising given the Campylobacter-specific fecal IgA and interferon gamma responses.
"These two measures of immunity have correlated with protection in previous clinical trials."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com